Related Experiment Video
Updated: Apr 26, 2026
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
The Paediatric migraine disability assessment score is a useful tool for evaluating prophylactic migraine treatment
Yasemin Topcu1, Semra Hiz Kurul1, Erhan Bayram1
1Division of Pediatric Neurology, Dokuz Eylul University Hospital, Izmir, Turkey.
Insights
The Paediatric Migraine Disability Assessment Score (PedMIDAS) effectively evaluates migraine drug efficacy in children. Topiramate and propranolol showed superior results compared to flunarizine in reducing migraine disability.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
- Migraine Research
Background:
- Migraine is a common neurological disorder in children.
- Objective assessment tools are needed to evaluate prophylactic treatments for pediatric migraine.
Purpose of the Study:
- To evaluate the Paediatric Migraine Disability Assessment Score (PedMIDAS) as an objective measure for assessing prophylactic drug effectiveness in children with migraine.
Main Methods:
- 88 children (6-17 years) with migraine were recruited.
- Treatment group (n=53) received topiramate, flunarizine, or propranolol; assessed with PedMIDAS at baseline, 3, and 6 months.
- Control group (n=35) received no prophylactic treatment; assessed with PedMIDAS every 3 months.
Main Results:
- Topiramate, propranolol, and flunarizine significantly reduced PedMIDAS scores, improving quality of life.
- Topiramate and propranolol demonstrated greater efficacy than flunarizine.
- Analgesic use decreased significantly with topiramate and propranolol, but not flunarizine.
Conclusions:
- PedMIDAS is a valuable tool for evaluating prophylactic therapy efficacy in pediatric migraine.
- Topiramate and propranolol are more effective than flunarizine in reducing migraine disability in children.
Aim:
There is a need for an objective assessment scoring system to evaluate the effectiveness of prophylactic drugs in paediatric migraine, and the aim of this study was to evaluate the Paediatric Migraine Disability Assessment Score (PedMIDAS).
Methods:
We recruited 88 children aged between 6 and 17 years of age with migraine. The 53 children in the treatment group were divided into three groups according to the prophylactic drug they received topiramate, flunarizine and propranolol and assessed using PedMIDAS before the start of treatment and 3 and 6 months after treatment. The 35 patients in the control group did not receive prophylactic treatment and were assessed with PedMIDAS on three occasions, 3 months apart.
Results:
Topiramate, propranolol and flunarizine treatments significantly decreased PedMIDASs and were shown to be effective in improving the patients' quality of life. Topiramate and propranolol were more effective than flunarizine. The number of days on analgesic treatment significantly decreased in the patients who had received topiramate and propranolol treatments (p < 0.05), but remained unchanged in the flunarizine prophylaxis group (p > 0.05).
Conclusion:
The PedMIDAS scoring system is useful in evaluating the efficacy of prophylactic therapy in paediatric migraine. Topiramate and propranolol lowered the PedMIDASs better than flunarizine.
